Sickle cell bone disease and response to intravenous bisphosphonates in children
Open Access
- 29 July 2022
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 33 (11) , 2397-2408
Abstract
Summary Children with sickle cell disease (SCD) have the potential for extensive and early-onset bone morbidity. This study reports on the diversity of bone morbidity seen in children with SCD followed at three tertiary centers. IV bisphosphonates were effective for bone pain analgesia and did not trigger sickle cell complications. Introduction To evaluate bone morbidity and the response to intravenous (IV) bisphosphonate therapy in children with SCD. Methods We conducted a retrospective review of patient records from 2003 to 2019 at three Canadian pediatric tertiary care centers. Radiographs, magnetic resonance images, and computed tomography scans were reviewed for the presence of avascular necrosis (AVN), bone infarcts, and myositis. IV bisphosphonates were offered for bone pain management. Bone mineral density was assessed by dual-energy X-ray absorptiometry (DXA). Results Forty-six children (20 girls, 43%) had bone morbidity at a mean age of 11.8 years (SD 3.9) including AVN of the femoral (17/46, 37%) and humeral (8/46, 17%) heads, H-shaped vertebral body deformities due to endplate infarcts (35/46, 76%), and non-vertebral body skeletal infarcts (15/46, 32%). Five children (5/26, 19%) had myositis overlying areas of AVN or bone infarcts visualized on magnetic resonance imaging. Twenty-three children (8/23 girls) received IV bisphosphonate therapy. They all reported significant or complete resolution of bone pain. There were no reports of sickle cell hemolytic crises, pain crises, or stroke attributed to IV bisphosphonate therapy. Conclusion Children with SCD have the potential for extensive and early-onset bone morbidity. In this series, IV bisphosphonates were effective for bone pain analgesia and did not trigger sickle cell complications.Keywords
This publication has 56 references indexed in Scilit:
- Revised Reference Curves for Bone Mineral Content and Areal Bone Mineral Density According to Age and Sex for Black and Non-Black Children: Results of the Bone Mineral Density in Childhood StudyThe Journal of Clinical Endocrinology & Metabolism, 2011
- The use of zoledronic acid in pediatric cancer patientsPediatric Blood & Cancer, 2010
- Myonecrosis in Sickle Cell Anemia—Overlooked and UnderdiagnosedCase Reports in Medicine, 2010
- Height Adjustment in Assessing Dual Energy X-Ray Absorptiometry Measurements of Bone Mass and Density in ChildrenThe Journal of Clinical Endocrinology & Metabolism, 2010
- Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockadeCochrane Database of Systematic Reviews, 2009
- Advanced Vertebral Fracture Among Newly Diagnosed Children With Acute Lymphoblastic Leukemia: Results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Research ProgramJournal of Bone and Mineral Research, 2009
- Bone involvement in sickle cell diseaseBritish Journal of Haematology, 2005
- Bisphosphonates for the relief of pain secondary to bone metastasesCochrane Database of Systematic Reviews, 2002
- Avascular Necrosis of the Hip in Children with Sickle Cell Disease and High Hb F: Magnetic Resonance Imaging Findings and Influence of α-Thalassemia TraitActa Haematologica, 2001
- Cyclic Administration of Pamidronate in Children with Severe Osteogenesis ImperfectaNew England Journal of Medicine, 1998